Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-55308942 in Bipolar Depression
NCT05328297Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing JNJ-55308942 with Placebo (2 arms). Primary endpoint: Change From Baseline in Montgomery-Asberg Depression Rating Scale Total Score at 6 weeks. Started Jun 2022; status: completed.
02
Drugs
zanvipixant
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT05328297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328297.